Clinical Value of New Staging Systems for Multiple Myeloma

Jung-Hye Choi; Jae-Hoon Yoon; Seong-Kyu Yang

doi:10.4143/crt.2007.39.4.171

Articles

Page Path: HOME > Cancer Res Treat > Volume 39(4); 2007 > Article

Original Article Clinical Value of New Staging Systems for Multiple Myeloma: Jung-Hye Choi, M.D., Ph.D., Jae-Hoon Yoon, M.D., Seong-Kyu Yang, M.D.; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2007;39(4):171-174.
DOI: https://doi.org/10.4143/crt.2007.39.4.171
Published online: December 31, 2007

Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea.

Correspondence: Jung-Hye Choi, Department of Internal Medicine, Hanyang University Guri Hospital, 249-1, Gyomun-dong, Guri 471-701, Korea. (Tel) 82-31-560-2236, (Fax) 82-31-553-7369, jhcmd@hanyang.ac.kr

• Received: September 24, 2007 • Accepted: November 1, 2007

9,257 Views
31 Download
6 Crossref

prev next

Full Article

Download PDF

Abstract

Purpose
We wanted to investigate the validity of the recently introduced Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) by comparing both systems with the widely accepted Durie/Salmon (DS) system for multiple myeloma patients.
Materials and Methods
Between 1992 and 2005, 85 multiple myeloma patients (men: women 41:44, median age: 63 years (range: 36~87)) with available baseline values of albumin and β₂-microglobulin were enrolled. The clinical and laboratory data were retrospectively obtained.
Results
According to the ISS, 11 patients were stage I (12.9%), 30 patients stage II (35.3%) and 44 patients stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6 months, 31.8 months and 15.1 months, respectively (p=0.015). The DS staging system was not able to predict the survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients stage II (31.8%), 27 patients stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system stage I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075).
Conclusion
The ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients.
Key words: Southwest Oncology Group staging system, International Staging System, Multiple myeloma

INTRODUCTION

Since the mid-1970s, the Durie/Salmon (DS) system has been the most widely used staging system for multiple myeloma (1). It uses several variables, including hemoglobin, calcium, monoclonal protein, the number of bone lesions and creatinine. Although the DS system has been proven to be an effective staging tool for patients with multiple myeloma, several problems have developed with the use of this staging system such as the complexity and difficulty in evaluating the lytic bone lesions as this evaluation is observer dependent. Thus, a more reliable staging system is needed.

Two new staging systems, the Southwest Oncology Group (SWOG) staging system and the International Staging System (ISS) have recently been developed (2,3). Both the SWOG and ISS staging systems are based on the serum β₂-microglobulin and serum albumin levels, which are two important prognostic factors for multiple myeloma patients. The difference between these two systems is that the ISS consists of 3 stages whereas the SWOG staging system consists of 4 stages.

There is little data on the SWOG staging system and the ISS in Korea. Therefore, to investigate the validity of these two new staging systems for predicting survival, we compared the DS staging system, the SWOG staging system and the ISS in Korean patients with multiple myeloma.

MATERIALS AND METHODS

Between 1992 and 2005, we enrolled a total of 85 consecutive patients who were diagnosed with multiple myeloma at Hanyang University Hospital and their baseline values of albumin and β₂-microglobulin were available. Forty-one (48.2%) were men and 44 (51.8%) were women and their median age was 63 years (range: 36~87). The clinical and laboratory data were retrospectively obtained. The collected data included their age at diagnosis, gender, the type and amount of M protein, hemoglobin, the platelet count, the serum calcium, LDH, creatinine, albumin and β₂-microglobulin, the number of lytic bone lesions and the percentage of bone marrow plasma cells. The institutional review board of Hanyang University Guri Hospital approved this study.

For comparison of the three staging systems, the patients were initially classified as DS stage I, II and III. The same patients were then restaged using the SWOG staging system and the ISS, according to their serum β₂-microglobulin and serum albumin levels at the time of diagnosis. The SWOG staging system and the ISS are shown in Table 1.

Overall survival was measured from the date of diagnosis to the date of death or the last follow-up. Survival curves were estimated using the Kaplan-Meier method and they were compared with the log-rank test. Stepwise Cox's regression analysis was performed to identify the prognostic factors for survival. For all tests, p<0.05 was considered statistically significant.

RESULTS

1) Patient characteristics

The most common type of multiple myeloma was IgG (52.9%), followed by IgA (22.4%), light chain (21.2%), IgD (2.4%), and one case of the non-secretory type. The median percentage of plasma cells in the bone marrow of the patients was 40%. Nineteen patients received high dose therapy with autologous stem cell transplantation and 65 patients were treated with conventional chemotherapy such as melphalan and prednisone, the M2 protocol (cyclophosphamide, vincristine, BCNU, melphalan and prednisone), or VAD (vincristine, adriamycin and dexamethasone). The number of deaths was forty-nine (57.6%). The most common cause of death was disease progression (40 patients), while other causes of death included infection (7 patients), acute myocardiac infarction (1 patient) and hepatoma (1 patient). The median follow-up duration was 64.4 months and the median overall survival for all patients was 25.4 months.

2) Survival according to the 3 staging systems

When staged by the DS system, 10 patients were stage I (11.8%), 6 patients were stage II (7.1%) and 69 patients were stage III (81.2%). The median survivals of each DS stage were 38.6 months for stage I, not reached for stage II (the median follow-up duration of the stage II patients was 32.5 months), and 19.4 months for stage III (p=0.29, Fig. 1A). The DS staging system was not able to predict survival. For the SWOG staging system, 14 patients were stage I (16.4%), 27 patients were stage II (31.8%), 27 patients were stage III (31.8%) and 17 patients were stage IV (20.0%). The median survivals of the SWOG staging system for stages I, II, III and IV were 78.6 months, 31.8 months, 11.6 months and 24.8 months, respectively (p=0.0075, Fig. 1B). The median survival for stage IV was longer than that for stage III. For the ISS, 11 patients were stage I (12.9%), 30 patients were stage II (35.3%) and 44 patients were stage III (51.8%). The median survivals of the ISS stages I, II and III were 78.6, 31.8 and 15.1 months, respectively (p=0.015, Fig. 1C). The ISS provided the best prediction of overall survival for multiple myeloma patients.

3) Prognostic factors

Other variables associated with significantly shorter survival according to the univariate analysis included a hemoglobin level <8.5 g/dL (p=0.016), a platelet count<100,000/µl (p=0.027), a creatinine level ≥2 mg/dl (p=0.002), a calcium level >12 mg/dl (p=0.016), a bone marrow plasma cell count ≥30% (p=0.02) and an elevated LDH level (p=0.047, Table 2). Multivariate analysis revealed that none of these were independent significant prognostic factors for improved overall survival.

DISCUSSION

Because of the various outcomes of patients with multiple myeloma, determining the prognostic factors of multiple myeloma is important for predicting disease outcome and determining the treatment method. Until now, a number of prognostic factors have been identified including hemoglobin, calcium, creatinine, β₂-microglobulin (4,5), albumin (6), C-reactive protein (7), the plasma cell labeling index (8) and chromosomal 13 deletion or other chromosomal abnormalities (9). Among these, β₂-microglobulin has been the single most important prognostic factor for predicting survival and it is correlated with the tumor burden and renal function (6). The serum albumin may reflect the interleukin-6 levels, the liver function and the nutritional status (2).

The ISS was developed based on data analysis of 10,750 previously untreated myeloma patients from 15 Asian, European and North American institutions and groups (3). β₂-microglobulin and albumin were selected because they were statistically powerful prognostic factors and these required only simple inexpensive tests. The median survivals of ISS stage I, II and III were 62, 44, and 29 months, respectively (p<0.0001). In addition, the ISS was demonstrated to be an effective system regardless of the geographic region, age and treatment type (3).

It was recently published that the SWOG and the ISS systems at the time of diagnosis could predict the prognosis of multiple myeloma patients who have undergone high dose chemotherapy with autologous peripheral stem cell transplantation as a first-line therapy (10). Furthermore, it was also published that the overall survival could be predicted by the SWOG system (p=0.02) and the ISS (p=0.01), but not by the DS staging system (p=0.25). One study that evaluated the significance of five staging systems in 470 multiple myeloma patients showed the superiority of the ISS over the DS staging system and the other prognostic classifications based on a combination of β₂-microglobulin and albumin (11).

Our study showed similar results. The DS system could not show a significant survival difference between stages I, II, and III. Using the ISS and SWOG staging system at diagnosis, the overall survival was significantly different among the multiple myeloma patients of each stage.

However, in our study, the median survival of stage IV patients in the SWOG staging system was longer than that for the stage III patient. Another study by Kim (10) also showed similar results in that the median survival of stage IV (45.5 months) was longer than that of stage III (37.1 months). Yet another previous study (11) revealed that the overall survival was similar between patients in SWOG stage III (23 months) and IV (21 months). The difference between SWOG stages III and IV was the serum albumin level, and although these studies included a relatively small number of patients, these results suggest that the prognostic value of albumin might be weak for patients with high β₂-microglobulin levels. So, the ISS may be a more reliable and predictable system than the DS and the SWOG staging systems.

Our study has several limitations. First, the treatment methods of the patients were heterogeneous. Second, the clinical data was analyzed retrospectively. Third, a relatively small number of patients were examined in this study. Nevertheless, our results suggested that the ISS might be a more useful, reliable and simple staging system for multiple myeloma patients than either the SWOG or DS staging systems.

CONCLUSION

In our study, the ISS staging system showed better reliability, simplicity and predictability for survival than the DS and SWOG staging systems for multiple myeloma patients.

REFERENCES

1. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–854. PMID: 1182674Article PubMed
2. Jacobson JL, Hussein MA, Barlogie B, Durie BG, Crowley JJ. Southwest Oncology GroupA new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003;122:441–450. PMID: 12877671Article PubMed
3. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–3420. PMID: 15809451Article PubMed
4. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983;55:439–447. PMID: 6357266Article PubMed
5. Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, et al. Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990;75:823–830. PMID: 2405920Article PubMed
6. Bataille R, Durie BG, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol. 1986;4:80–87. PMID: 3510284Article PubMed
7. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733–737. PMID: 1638024Article PubMed
8. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382–3387. PMID: 8507875Article PubMed
9. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250–4256. PMID: 7492784Article PubMed
10. Kim H, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, et al. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. Biol Blood Marrow Transplant. 2006;12:837–844. PMID: 16864054Article PubMed
11. Mihou D, Katodritou I, Zervas K. Evaluation of five staging systems in 470 patients with multiple myeloma. Haematologica. 2006;91:1149–1150. PMID: 16885059PubMed

Fig. 1

Overall survival of the 85 multiple myeloma patients according to the DS staging system (A), the SWOG staging system (B) and the ISS (C).

Table 1

The SWOG staging system and the international staging system (ISS) for multiple myeloma patients

^*β₂-microglobulin.

Table 2

Results of univariate analysis of the factors that influence the overall survival

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity
Angel T. Chan, William Dinsfriend, Jiwon Kim, Brian Yum, Razia Sultana, Christopher A. Klebanoff, Andrew Plodkowski, Rocio Perez Johnston, Michelle S. Ginsberg, Jennifer Liu, Raymond J. Kim, Richard Steingart, Jonathan W. Weinsaft
Journal of Cardiovascular Magnetic Resonance.2021; 23(1): 42. CrossRef
Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience
Hyun Ae Jung, Mi-Ae Jang, Kihyun Kim, Sun-Hee Kim
Annals of Laboratory Medicine.2018; 38(3): 196. CrossRef
The Role of18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems
Shengming Deng, Bin Zhang, Yeye Zhou, Xin Xu, Jihui Li, Shibiao Sang, Wei Zhang
Contrast Media & Molecular Imaging.2018; 2018: 1. CrossRef
Biochemical and electrophoretic evaluation of Clinically suspected multiple myeloma
R SREEVANI NAMANI, DR LAXMI NARAYANA SRIPURAM
International Journal of Pharma and Bio Sciences.2017;[Epub] CrossRef
Reconstruction of multiple myeloma lesions around the pelvis and acetabulum
Vasileios I. Sakellariou, Andreas F. Mavrogenis, Olga Savvidou, Franklin H. Sim, Panayiotis J. Papagelopoulos
European Journal of Orthopaedic Surgery & Traumatology.2015; 25(4): 643. CrossRef
Retrospective analysis of 264 multiple myeloma patients
CHUANYING GENG, NIAN LIU, GUANGZHONG YANG, AIJUN LIU, YUN LENG, HUIJUAN WANG, LIHONG LI, YIN WU, YANCHEN LI, WENMING CHEN
Oncology Letters.2013; 5(2): 707. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical Value of New Staging Systems for Multiple Myeloma

Cancer Res Treat. 2007;39(4):171-174. Published online December 31, 2007

DOI: https://doi.org/10.4143/crt.2007.39.4.171

XML Download

Abstract
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
CONCLUSION
REFERENCES

Clinical Value of New Staging Systems for Multiple Myeloma

Fig. 1 Overall survival of the 85 multiple myeloma patients according to the DS staging system (A), the SWOG staging system (B) and the ISS (C).

Fig. 1

Clinical Value of New Staging Systems for Multiple Myeloma

Table 1

The SWOG staging system and the international staging system (ISS) for multiple myeloma patients

^*β₂-microglobulin.

Table 2

Results of univariate analysis of the factors that influence the overall survival

Table 1 The SWOG staging system and the international staging system (ISS) for multiple myeloma patients

^*β₂-microglobulin.

Table 2 Results of univariate analysis of the factors that influence the overall survival